Almax Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Almax Pharma
Largest movements
- Receivables within one year -€13,149
down €13,149 (-3.7%), from €357,903 to €344,754
of which Trade receivables: -€18,014
- Tangible fixed assets -€4,472
no longer reported in 2025 (was €4,472)
- Tax, wage and social debts -€23,601
down €23,601 (-45.1%), from €52,281 to €28,680
- Trade debts +€7,764
up €7,764 (+114.5%), from €6,783 to €14,547
- Financial charges +€15,173
up €15,173 (+410.6%), from €3,696 to €18,869
of which Non-recurring financial charges: +€12,982
- Gross operating margin -€3,344
down €3,344 (-10.1%), from €33,155 to €29,811
- Depreciation -€2,500
no longer reported in 2025 (was €2,500)
- Other operating charges -€1,884
down €1,884 (-90.7%), from €2,076 to €192
- Taxes +€1,709
up €1,709 (+24.5%), from €6,972 to €8,681
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €362,807 | €346,656 | -€16,151 | -4.5% |
| Fixed assets | 21/28 | €4,472 | - | -€4,472 | |
| Tangible fixed assets | 22/27 | €4,472 | - | -€4,472 | |
| Furniture and vehicles | 24 | €4,472 | - | -€4,472 | |
| Current assets | 29/58 | €358,335 | €346,656 | -€11,680 | -3.3% |
| Amounts receivable within one year | 40/41 | €357,903 | €344,754 | -€13,149 | -3.7% |
| Trade receivables | 40 | €18,014 | - | -€18,014 | |
| Other amounts receivable | 41 | €339,889 | €344,754 | +€4,865 | +1.4% |
| Cash at bank and in hand | 54/58 | €219 | €1,467 | +€1,248 | +570.9% |
| Deferred charges and accrued income | 490/1 | €214 | €435 | +€221 | +103.4% |
| Total equity and liabilities | 10/49 | €362,807 | €346,656 | -€16,151 | -4.5% |
| Equity | 10/15 | €301,359 | €303,429 | +€2,070 | +0.7% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | - | -€6,200 | |
| Issued capital | 100 | €18,600 | - | -€18,600 | |
| Uncalled capital | 101 | €12,400 | - | -€12,400 | |
| Reserves | 13 | €1,860 | €1,860 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Legal reserve | 130 | €1,860 | - | -€1,860 | |
| Reserves not available under the articles | 1311 | - | €1,860 | +€1,860 | |
| Profit (loss) carried forward | 14 | €293,299 | €295,369 | +€2,070 | +0.7% |
| Amounts payable | 17/49 | €61,448 | €43,227 | -€18,221 | -29.7% |
| Amounts payable within one year | 42/48 | €61,448 | €43,227 | -€18,221 | -29.7% |
| Financial debts | 43 | €2,384 | - | -€2,384 | |
| Credit institutions | 430/8 | €2,384 | - | -€2,384 | |
| Trade debts | 44 | €6,783 | €14,547 | +€7,764 | +114.5% |
| Suppliers | 440/4 | €6,783 | €14,547 | +€7,764 | +114.5% |
| Taxes, remuneration and social security | 45 | €52,281 | €28,680 | -€23,601 | -45.1% |
| Taxes | 450/3 | €52,281 | €28,680 | -€23,601 | -45.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,500 | - | -€2,500 | |
| Other operating charges | 640/8 | €2,076 | €192 | -€1,884 | -90.7% |
| Non-recurring operating charges | 66A | €365 | - | -€365 | |
| Gross operating margin | 9900 | €33,155 | €29,811 | -€3,344 | -10.1% |
| Operating profit (loss) | 9901 | €28,214 | €29,619 | +€1,405 | +5.0% |
| Financial charges | 65/66B | €3,696 | €18,869 | +€15,173 | +410.6% |
| Recurring financial charges | 65 | €3,696 | €5,887 | +€2,191 | +59.3% |
| Non-recurring financial charges | 66B | - | €12,982 | +€12,982 | |
| Profit (loss) for the period before taxes | 9903 | €24,519 | €10,751 | -€13,768 | -56.2% |
| Income taxes | 67/77 | €6,972 | €8,681 | +€1,709 | +24.5% |
| Profit (loss) for the period | 9904 | €17,547 | €2,070 | -€15,477 | -88.2% |
| Profit (loss) for the period to be appropriated | 9905 | €17,547 | €2,070 | -€15,477 | -88.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.